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Broadly  neutralizing  antibodies  against  human  immunodeﬁciency  virus  type  1 (HIV-1)  are  considered
vital  components  of novel  therapeutics  and  blueprints  for vaccine  research.  Yet escape  to  even  the  most
potent  of these  antibodies  is  imminent  in natural  infection.  Measures  to  deﬁne  antibody  efﬁcacy  and
prevent  mutant  selection  are  thus  urgently  needed.  Here,  we  derive  a mathematical  framework  to  pre-
dict the  concentration  ranges  for which  antibody  escape  variants  can  outcompete  their  viral  ancestors,
referred  to as  mutant  selection  window  (MSW).  When  determining  the  MSW,  we focus  on the  differential
efﬁcacy  of  neutralizing  antibodies  against  HIV-1  in two canonical  infection  routes,  free-virus  infection
and  cell–cell  transmission.  The  latter  has  proven  highly  effective  in  vitro  suggesting  its importance  for
both  in  vivo  spread  as well  as  for escaping  targeted  intervention  strategies.  We  observed  a  range  of  MSW
patterns  that  highlight  the potential  of mutants  to arise  in  both  transmission  pathways  and  over  wide
concentration  ranges.  Most  importantly,  we  found  that  only  when  the arising  mutant  has both,  residual
sensitivity  to the  neutralizing  antibody  and  reduced  infectivity  compared  to the  parental  virus,  antibody
dosing  outside  of  the  MSW  to  restrict  mutant  selection  is  possible.  Emergence  of  mutants  that  provide
complete  escape  and  have no  considerable  ﬁtness  loss  cannot  be  prevented  by  adjusting  antibody  doses.
The  latter  may  in part explain  the  ubiquitous  resistance  to neutralizing  antibodies  observed  in  natural
infection  and  antibody  treatment.  Based  on our ﬁndings,  combinations  of antibodies  targeting  different
epitopes  should  be favored  for antibody-based  interventions  as this  may  render  complete  resistance  less
likely  to occur  and  also  increase  chances  that multiple  escapes  result  in  severe  ﬁtness  loss  of  the virus
making  longer-term  antibody  treatment  more  feasible.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
During human immunodeﬁciency virus type 1 (HIV-1) infec-
tion, the neutralizing antibody response directed against the viral
envelope (Env) proteins gp120 and gp41 co-evolves with the viral
quasispecies (Frost et al., 2005; Overbaugh and Morris, 2012;
Wibmer et al., 2013). In natural infection and antibody-based treat-
ment, viral escape occurs even against the most potent broadly
neutralizing antibodies (bnAb) highlighted by the fact that although
bnAbs combine high potency and efﬁcacy across divergent HIV-1
strains, they all have been isolated from individuals who acquired
resistance and failed to control viremia (Klein et al., 2012; Trkola
et al., 2005; Mascola and Haynes, 2013; Derdeyn et al., 2014; Caskey
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et al., 2015). Despite this, there is general agreement that bnAbs
have an enormous potential in treatment and as blueprints for the
design of protective vaccines provided that effective doses can be
maintained in vivo (Burton et al., 2012; Schiffner et al., 2013).
In order to render antibody therapy successful, measures are
needed to prevent or limit the evolution of neutralization resis-
tant viral variants. Here, we present a framework to determine the
sub-effective antibody concentration at which a resistant mutant
can outcompete its viral ancestor on the population level. This con-
centration range, referred to as mutant selection window (MSW), is
crucial to judge whether treatment regimes can be optimized to
prevent escape evolution. Determining this concentration range is,
however, complicated by the virus’ ability to transmit via two dif-
ferent routes. HIV-1, like many other enveloped viruses, can spread
as cell-free virus particles or via cell–cell transmission. Virus spread
via cell–cell transmission can occur through close-range cellular
interactions either via pre-existing cellular contact zones such as
the immunological synapse formed between dendritic cells and
CD4 T-cells (McDonald et al., 2003; Arrighi et al., 2004; Piguet and
http://dx.doi.org/10.1016/j.virusres.2015.10.009
0168-1702/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Steinman, 2007) or short- and longer range actin-containing struc-
tures like ﬁlopodia (Lehmann et al., 2005; Sherer et al., 2007) and
nanotubes (Sowinski et al., 2008). Best studied is the transmission
via contact zones between HIV-1 infected and uninfected T cells,
termed virological synapse (Jolly et al., 2004, 2007). This forms
upon binding of the viral envelope protein to the CD4 receptor,
leading to rapid recruitment and local concentration of Env, CD4,
co-receptors, and adhesion molecules on the infected and target
cells. While free-virus spread allows for transmission into more
distant tissues, cell–cell transmission is thought to aid the virus
to overcome physical and immunological barriers and has proven
most effective in vitro in case of HIV-1 (Sattentau, 2008).
HIV-1 cell–cell transmission has been studied intensively in vitro
using a variety of experimental assay systems that allowed the
visualization and quantiﬁcation of infection occurring through this
route demonstrating that cell–cell transmission is far more efﬁ-
cient than free-virus spread (Gupta et al., 1989; Dimitrov et al.,
1993; Jolly et al., 2004; Sherer et al., 2007; Sowinski et al., 2008;
Hubner et al., 2009; Martin et al., 2010; Dale et al., 2011; Sigal et al.,
2012; Abela et al., 2012; Permanyer et al., 2012a; Duncan et al.,
2013; Malbec et al., 2013; Russell et al., 2013; Titanji et al., 2013;
Zhong et al., 2013b, 2013; Agosto et al., 2014). One factor postulated
to enhance efﬁcacy is the clustering of receptors on effector cells
in the virological synapse which allows for simultaneous infection
by multiple virions (Rudnicka et al., 2009; Del Portillo et al., 2011;
Russell et al., 2013). The improved infectivity in the cell–cell trans-
mission pathway could be an important replication niche for unﬁt
virus variants to gather compensating mutations that boost their
replicative capacity (Brandenberg et al., 2014; Yen et al., 2014).
In addition to further experimental conﬁrmation, new analytic
and theory based strategies are needed to determine to which
extent cell–cell transmission occurs in vivo and which role it plays
for the establishment and spread of HIV-1 infection. How impor-
tant it is to address these questions has been illustrated by in vitro
studies revealing that antiretroviral therapy (ART) and broadly
neutralizing antibodies (bnAb) do not neutralize HIV-1 cell–cell
transmission with the same potency as free-virus spread (Poignard
et al., 1999; Chen et al., 2007; Massanella et al., 2009; Sigal et al.,
2012; Abela et al., 2012; Durham et al., 2012; Permanyer et al.,
2012b; Malbec et al., 2013; Titanji et al., 2013; Agosto et al., 2014;
McCoy et al., 2014; Reh et al., 2015). While the decreased efﬁciency
of reverse transcriptase inhibitors observed in vitro can be partially
explained by higher rates of virus transfer during cell–cell trans-
mission (Sigal et al., 2012; Permanyer et al., 2012b; Duncan et al.,
2013; Agosto et al., 2014), this appears not to be the only reason
for the reduced neutralization capacity of bnAbs, entry inhibitors
and other antiretroviral therapies (Sagar et al., 2012; Agosto et al.,
2014). We  recently showed that the neutralization efﬁciency of
bnAbs during free-virus and cell–cell transmission is inﬂuenced
by their neutralization kinetics: bnAbs were most potent against
free-virus transmission when they showed a high activity prior to
CD4 attachment of the virus, suggesting full access to their epitope
on the virus Env and high binding afﬁnity. On the contrary, bnAbs
that displayed a decreased activity pre-attachment and during free-
virus neutralization inhibited more potently after CD4 attachment
of the virus and better retained their activity during cell–cell trans-
mission (Reh et al., 2015). This is in accordance with previous
time-of-addition (Martin et al., 2010) and post-attachment stud-
ies (Binley et al., 2003; Abela et al., 2012) and indicates that the
functional characteristics of the antibody response to speciﬁc HIV-
1 strains determine the neutralization capacity during free-virus
and cell–cell transmission.
We  recently analyzed the consequences of decreased inhibitory
potentials of bnAbs during cell–cell transmission by comparing the
probabilities that an antibody neutralization resistant viral variant
arises via cell–cell and free-virus transmission (Reh et al., 2015).
We  showed that it is more likely for an escape mutant to arise
during cell–cell transmission than during free-virus transmission.
Thus, the cell–cell route could indeed serve as a rescue pathway
for the virus, both against antiretroviral therapy and the antibody
response.
Depending on the potency and type of antibody studied, escape
even to broadly neutralizing antibodies can be rapid in vivo
(Mascola et al., 2000; Trkola et al., 2005; Hessell et al., 2009, 2010;
Moldt et al., 2012; Barouch et al., 2013; Halper-Stromberg et al.,
2014; Klein et al., 2014; Doria-Rose et al., 2014; Caskey et al., 2015).
A number of factors contribute to antibody neutralization efﬁcacy
in vivo, including tissue distribution, half-life, and the potential
to elicit effector functions (Hessell et al., 2009; Bournazos et al.,
2014; Ko et al., 2014; Trkola, 2014). Here, we  seek to quantify the
concentration ranges for which a speciﬁc antibody neutralization
resistant variant can outcompete its viral ancestor because dosing
to ensure inhibitory activity at levels that are above the limits of this
MSW  would be desirable. Determining the concentration ranges for
which an antibody escape variant can outcompete its viral ancestor
may  help to understand the in vivo efﬁcacy of neutralizing antibod-
ies both as components of vaccines or as therapeutics. To this end,
we extend the MSW  theory (Baquero and Negri, 1997; Gullberg
et al., 2011; Rosenbloom et al., 2012), to settings of HIV-1 neutral-
ization by antibodies during free-virus and cell–cell infection. We
calculate the MSW  during free-virus and cell–cell infection as both
Ab potency and virus infectivity can widely differ depending on
the transmission pathway (Abela et al., 2012; Malbec et al., 2013;
Zhong et al., 2013; McCoy et al., 2014; Brandenberg et al., 2014;
Gombos et al., 2015; Reh et al., 2015). As we show here, the MSW
of both pathways covers large concentration ranges. Deﬁnition of
antibody doses above the critical range, the upper boundary of the
MSW,  is not possible in many cases, particularly when the emerg-
ing mutant has gained complete resistance to antibody inhibition
without severe losses in ﬁtness. In summary, our ﬁndings provide
new insight into why escape to neutralizing antibodies is immi-
nent in HIV-1 infection and highlight that neutralizing antibody
therapy in the long term can only be effective if several antibodies
are combined as a strategy to restrict rapid emergence of com-
plete resistance combined with an antibody dosage above the upper
border of the combined MSWs.
2. Materials and methods: studying antibody induced
escape mutations
In this section we  explain the experimental methods necessary
to perform the mutant selection analysis. The derivation of the
MSW  model itself is laid out in Section 3.1.
2.1. General introduction to experimental methods
We  and others (Mazurov et al., 2010; Abela et al., 2012; Janaka
et al., 2013; Zhong et al., 2013; Reh et al., 2015) have recently
established an assay system to exclusively analyze in vitro HIV-1
free-virus and cell–cell transmission. In short, Env pseudotyped
virions are produced by a producer cell line. The pseudovirions
are able to infect target cells only once (single-round). Upon infec-
tion, a luminescent marker is expressed through which infection
of a target cell line can be monitored. To analyze neutralization,
infection of the target cells is performed in the presence of increas-
ing antibody concentration. We  utilized two systems to distinguish
cell–cell from free-virus transmission as recently described by (Reh
et al., 2015): (i) To guarantee free-virus transmission, we only use
the virions produced by the virus producer cell and add a catalyst
which helps the virions to bind to and enter the target cells. (ii)
To exclusively study cell–cell transmission, we  transfer only the
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Table  1
Overview of all bnAbs used in this study, reference of their ﬁrst description and sources.
Inhibitor Drug class Target/Epitope Reference Source
b12 Antibody gp120, CD4-bs Barbas et al. (1992) D. Burton, The Scripps Research Institute, La Jolla, USA
PG9  Antibody gp120, V1V2 peptidoglycan Walker et al. (2009) D. Burton, The Scripps Research Institute, La Jolla, USA
PG16  Antibody gp120, V1V2 peptidoglycan Walker et al. (2009) D. Burton, The Scripps Research Institute, La Jolla, USA
2G12  Antibody Outer domain glycan Trkola et al. (1996) D. Katinger, Polymun, Vienna, Austria
PGT121  Antibody gp120, V3 peptidoglycan Walker et al. (2011) D. Burton, The Scripps Research Institute, La Jolla, USA
PGT128  Antibody gp120, V3 peptidoglycan Walker et al. (2011) D. Burton, The Scripps Research Institute, La Jolla, USA
2F5  Antibody gp41, MPER (671-676) Muster et al. (1993) D. Katinger, Polymun, Vienna, Austria
infected producer cells and omit the catalyst to prevent free virions
from binding to the target cells.
2.2. Reagents
Properties and sources of bnAbs used in this study are listed in
Table 1. We  thank D. Burton and D. Katinger for providing antibod-
ies.
2.3. Cells
293-T cells were obtained from the American Type Culture
Collection (ATCC), A3.01-CCR5 cells were described previously
(Buttke and Folks, 1992; Abela et al., 2012). 293-T cells were
cultivated in DMEM with 10% heat inactivated FCS and 1% Peni-
cillin/Streptomycin. A3.01-CCR5 cells were maintained in RPMI
with 10% heat inactivated FCS and 1% Penicillin/Streptomycin.
2.4. Viruses
Plasmids encoding the envelope of strains BG505 (subtype A),
JR-FL, JR-CSF, SF162, REJO, AC10 (all subtype B) and ZM109 (sub-
type C) were obtained from the NIH ARP. Envelope (env) point
mutations to achieve bnAb resistance (Table 2) were generated
by site-directed mutagenesis (Agilent QuikChange II XL) accord-
ing to the manufacturer instructions and sequenced by in-house
Sanger sequencing to conﬁrm presence of the desired mutations
and absence of unintended sequence changes. For the produc-
tion of single-round replicating pseudovirus stocks, 293-T cells
were transfected with the respective viral pseudo typing constructs
and env expression plasmids as described (Rusert et al., 2009).
The following constructs were used: The luciferase reporter HIV-1
pseudotyped vector pNLlucAM (Rusert et al., 2011) (a gift from Dr.
A. Marzosan) and the NL4-3 based pseudotyped vector with inte-
grated inGluc reporter construct (NLinGluc (Janaka et al., 2013); a
gift from Dr. M.  Johnson).
2.5. Neutralization of cell-free Env-pseudotyped virus on
A3.01-CCR5
Free-virus inhibition by bnAbs was assessed on A3.01-CCR5 cells
using Env-pseudotyped NLlucAM reporter viruses. Virus stocks
were harvested from 293-T 6-well cultures 48h post transfection
and diluted 1:1 with culture medium (DMEM, 10% FCS, antibiotics).
Viruses and serial dilutions of bnAbs were pre-incubated for 1h at
37 ◦C and added to 5 × 104 A3.01-CCR5 target cells in 96 well cul-
ture plates in the presence of 10 g/ml diethylaminoethyl (DEAE,
Amersham Biosciences, Connecticut, USA). After 65 h incubation at
37 ◦C, infection was assessed by luciferase reporter production after
cell lysis and addition of ﬁreﬂy luciferase substrate (Promega, Madi-
son, Wisconsin, USA). Emitted RLU were quantiﬁed on a Dynex MLX
luminometer (Dynex Technologies Inc., Chantilly, Virginia, USA).
The inhibitor concentrations causing 50% reduction in viral infec-
tivity (50% inhibitory concentration; IC50) and the inhibition curve
slopes were calculated by ﬁtting pooled data from two to three
independent experiments to sigmoid dose response curves (vari-
able slope) using GraphPad Prism. For more details on the ﬁtting
algorithm please consult the Prism ﬁtting guide (Graphpad Prism,
2015).
2.6. Assessing neutralization activity during cell–cell
transmission of 293-T to A3.01-CCR5 cells
Neutralization of HIV-1 cell–cell transmission was analyzed
on Env-pseudotyped NLinGluc virus transfected 293-T donor cells
and A3.01-CCR5 target cells as recently described (Mazurov et al.,
2010; Janaka et al., 2013; Zhong et al., 2013; Reh et al., 2015). The
inGluc vector allows for distinction of cell–cell transmission from
cell-fusion events. To exclusively study cell–cell transmission, free-
virus infectivity was further restricted by the omission of DEAE in
the infection media as previously described (Abela et al., 2012; Reh
et al., 2015). For assessing neutralization of cell–cell transmission,
293-T cell 6-well cultures were transfected with env and NLinGluc
plasmids in a 1:3 ratio. 6 h post transfection cells were collected,
5 × 103 cells seeded as infected donor cells per 96 well culture plate,
and serial dilutions of inhibitors were added. After 1h incubation
at 37 ◦C, 1.5 × 104 A3.01-CCR5 target cells in RPMI medium were
added to the 293-T-inhibitor mix. After 65 h of incubation at 37 ◦C,
Gaussia luciferase activity in the supernatant was quantiﬁed using
the Renilla Luciferase Assay System (Promega, Madison Wisconsin,
USA) according to the manufacturers’ instructions. Neutralization
data were analyzed with GraphPad Prism as described above.
2.7. Determination of entry ﬁtness reduction of mutant strain
envelopes in absence of antibodies, r
To derive an estimate for viral entry ﬁtness in free-virus trans-
mission, cell-free virus preparations of Env-pseudotyped NLlucAM
reporter viruses were generated for all sensitive and resistant
viruses using identical transfection conditions in 6-well plates.
Infectivity of a set input (25 l virus stock solution per 96-well)
was then determined for all virus preparations in 2–3 independent
experiments. Infectivity was  measured in emitted RLU as quantiﬁed
by the Dynex MLX  luminometer (Dynex Technologies Inc., Chan-
tilly, Virginia, USA). RLU values were averaged across all replicates
in the independent experiments and used as estimate of entry ﬁt-
ness. Entry ﬁtness during cell–cell transmission was  determined in
analogy using transfected 293-T cells instead of virus supernatant
as input (5 × 103 transfected 293-T cells per 96-well). We  obtained
the ﬁtness ratio of the mutant strain, r, by dividing the average RLU
for the resistant by the one for the sensitive strain.
3. Results
3.1. A framework to study evolution of resistant viral variants in
cell–cell versus free-virus spread
While we  learned from earlier work that broadly neutralizing
antibody escape variants of HIV-1 are overall more likely to arise
during cell–cell than free-virus transmission (Reh et al., 2015),
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Table 2
Overview over probed pairings of sensitive and resistant viral strains to neutralization of the designated antibody, their IC50s and slope values in cell–cell and free-virus
transmission determined with GraphPad Prism, and the ﬁtness ratio between antibody resistant and sensitive strain. The ﬁtness ratio is measured in absence of antibodies and
thus  only depends on the particular sensitive and resistant strain as well as the transmission route (ﬁrst three columns). If 50% inhibition was not reached with concentrations
below 100 g/ml the viral strain was  denoted resistant to the respective antibody (100% res).
Sensitive strain (sen) Resistant strain (res) Antibody Route IC50sen msen IC50res mres r
BG505 T332N BG505 PGT121 fv 0.003727 0.7525 0.2572 0.6019 0.5387
BG505 T332N BG505 PGT121 cc 0.3892 1.006 1.726 1 0.3632
BG505 T332N BG505 PGT128 fv 0.003879 0.4772 1.928 0.7843 0.5387
BG505 T332N BG505 PGT128 cc 0.4795 2.005 2.799 1.518 0.3632
JR-FLwt JR-FL M373RP370L b12 fv 0.002964 0.608 100% res 100% res 0.5287
JR-FLwt JR-FL M373RP370L b12 cc 0.3241 0.7493 100% res 100% res 0.3643
JR-FLwt JR-FL N332S 2G12 fv 0.3213 0.6606 100% res 100% res 0.876
JR-FLwt JR-FL N332S 2G12 cc 1.268 0.6218 100% res 100% res 0.8536
JR-FLwt JR-FL D664N 2F5 fv 0.0685 0.4762 100% res 100% res 1.2957
JR-FLwt  JR-FL D664N 2F5 cc 1.225 0.7412 100% res 100% res 1.063
JR-FL  E168KN189A JR-FLwt PG9 fv 0.04013 0.5142 100% res 100% res 1.4474
JR-FL  E168KN189A JR-FLwt PG9 cc 0.4056 0.955 100% res 100% res 1.4911
JR-FL  E168KN189A JR-FLwt PG16 fv 0.002178 0.4054 100% res 100% res 1.4474
JR-FL  E168KN189A JR-FLwt PG16 cc 0.02982 0.5041 100% res 100% res 1.4911
REJOwt  REJO N160K PG9 fv 0.03397 0.5473 100% res 100% res 0.6475
REJOwt REJO N160K PG9 cc 1.089 1.01 100% res 100% res 0.4927
ZM109wt ZM109 N160K PG9 fv 0.2887 0.4619 100% res 100% res 0.0636
ZM109wt ZM109 N160K PG9 cc 5.655 0.4091 100% res 100% res 0.4786
AC10wt AC10 N160K PG9 fv 0.2069 0.4802 100% res 100% res 0.4177
AC10wt AC10 N160K PG9 cc 0.9083 0.9159 100% res 100% res 0.7839
JR-CSFwt JR-CSF N160K PG9 fv 0.002547 0.6205 100% res 100% res 0.038
JR-CSFwt JR-CSF N160K PG9 cc 0.022 0.7148 100% res 100% res 0.1512
SF162 K160N SF162wt PG9 fv 0.004284 0.3252 100% res 100% res 0.2746
SF162 K160N SF162wt PG9 cc 0.2927 0.609 100% res 100% res 0.9747
concentration ranges for which a speciﬁc escape variant will arise
and outcompete the sensitive strain have not yet been deﬁned. We
determine these ranges by applying a framework introduced for
antibiotic killing of bacteria (Baquero and Negri, 1997; Gullberg
et al., 2011) and later applied to drug-resistance evolution in HIV-1
infection (Rosenbloom et al., 2012). Of note, this framework does
not make assumptions on whether the mutant strain is present
upon drug delivery or arises through mutation in presence of a
drug that is not 100% effective. For constructing the MSW, we com-
pare the ﬁtness of a virus’ antibody neutralization sensitive (wild
type) and Ab-resistant mutant strain. Here we use the term ﬁt-
ness in the sense of the replicative capacity which summarizes
virus production and infection of new cells. Without neutralizing
antibodies, the replicative capacity comprises only the viral base-
line ﬁtness, i.e. viral production and unhindered infection of new
cells. If, however, neutralizing antibodies are present, the number
of newly produced virions will be reduced through neutralization,
resulting in a lower replicative capacity. Whether a mutant strain
can outcompete its more sensitive viral ancestor thus depends on
the reduction of the ﬁtness by antibodies and in addition on the
baseline ﬁtness of both strains. All mathematical variables used in
the following are summarized in Table 3.
Table 3
Parameter deﬁnitions.
Ab Antibody
IC50a,sen Inhibitory concentration at which 50% of an antibody a’s
inhibitory potential is reached for the sensitive (wild type)
virus
ma,sen Hill slope of inhibition curve measured for antibody a and
a  sensitive (wild type) strain
c(Ab)  Antibody concentration
Fa,sen0 Fitness (replicative capacity) of the sensitive strain in
absence of antibody a, following (Rosenbloom et al., 2012),
we  set this parameter to Fa,sen0 = 10
Fa,res0 Fitness (replicative capacity) of the resistant strain (escape
mutation) against antibody a, in absence of antibody a
r  Fitness reduction for mutant variant in absence of
antibodies, i.e. Fa,res0 = rFsen0
We  determine the neutralizing effect of one bnAb at different
antibody concentrations in in vitro infectivity experiments (see
Section 2 for details on the experimental system and Fig. 1A). The
concentration at which 50% of the maximal inhibitory effect is
reached, denoted by IC50, and the Hill-slope parameter of the inhi-
bition curve, denoted by m,  are obtained by ﬁtting the Hill-curve
(Chou, 1976) to the data:
% inhibition = 100 × c(Ab)
m
c(Ab)m + IC50m (1)
where c(Ab) denotes the antibody concentration. Eq. (1) directly
translates into infectivity reduction, finf:
finf (c(Ab)) = 1 −
c(Ab)m
c(Ab)m + IC50m =
1
1 + (c(Ab)/IC50)m (2)
Without loss of generality, we  only explain the construction
of the MSW  in free-virus (fv) transmission. This mathematical
framework can, however, also be applied to the cell–cell route by
replacing the relevant measures by those obtained in the in vitro
cell–cell (cc) inhibition assay. For one antibody, a, we  measure its
inhibitory potential against the sensitive viral strain, va,sen, and
against the resistant antibody-escape mutant, va,res. We  denote
the corresponding IC50 and slope values with IC50a,sen, ma,sen and
IC50a,res, ma,res, respectively. The ﬁtness of the sensitive strain in
absence of antibodies is denoted by Fsen0 . As explained above, the
viral ﬁtness is a function of the antibody concentration. Using Eq.
(2), the wild type ﬁtness is
Fa,sen(c(Ab)) = Fsen0 finf (c(Ab)) =
Fsen0
1 + (c(Ab)/IC50a,sen)ma,sen
(3)
and for the mutant ﬁtness we  obtain:
Fa,res(c(Ab)) = F
res
0
1 + (c(Ab)/IC50a,res)ma,res
= rF
sen
0
1 + (c(Ab)/IC50a,res)ma,res
(4)
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Fig. 1. Determination of the MSW  for two  related viral strains of which one is sensitive to antibody neutralization and the other is a less sensitive mutant variant. (A) The
antibody inhibitory concentration at which 50% of the maximal effect is reached, IC50, determined in neutralization assays for both viral variants. (B) The ﬁtness curves for
the  sensitive and the resistant strains are plotted. The MSW  starts at the concentration cl (green dashed line) at which the ﬁtness of the resistant strain equals the ﬁtness of
the  sensitive strain and ends at the concentration cu (green dashed line) at which the ﬁtness is smaller than 1.
with the ﬁtness ratio r := Fres0 /Fsen0 . For estimating the MSW,  we
have to distinguish between two cases: (i) The mutation leads to
decreased neutralization sensitivity. As a consequence, both IC50
and slope values can be derived from in vitro inhibition experi-
ments (see Fig. 1A). (ii) The mutation leads to complete resistance
and neither IC50a,res nor ma,res can be estimated out of the in vitro
inhibition assays (see Fig. 2A).
(i) The mutation leads to decreased neutralization sensitivity. If the
IC50 and the slope parameters for both sensitive and resistant viral
strains can be determined, the mutant selection window is the con-
centration range for which the resistant mutant’s ﬁtness is bigger
than the sensitive strain’s ﬁtness and bigger than 1. Only in this
case, the resistant strain is able to outcompete the wild type strain
on a population level. The lower bound of the MSW,  ca
l
can theoret-
ically be calculated by setting Fa,sen(c(Ab)) = Fa,res(c(Ab)) and solving
this equation in respect to the antibody concentration, c(Ab). How-
ever, this is mathematically only possible, if the slope parameter
is an integer, in all other cases, the equation can only be solved
A B
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Fig. 2. Determination of the MSW  for two genetically related viral strains for which a point mutation confers complete resistance to antibody neutralization. (A) The IC50
of  the sensitive strain is determined by inhibition curves (black dots and ﬁtted Hill-curve shown as black line). The inhibition curve of the resistant strain (gray dots) shows
that  the resistant strain is completely inert against antibody neutralization. (B) The ﬁtness of the resistant strain (gray line) does not depend on the antibody concentration.
Thus,  the mutant selection window starts at the concentration cl (green dashed line) at which the ﬁtness of the sensitive strain is lower than the resistant strain.
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numerically. The upper bound of the MSW,  cau can be calculated
by solving 1 = Fa,res(c(Ab)) in respect to the antibody concentration.
Thus,
cau = IC50a,res(rFsen0 − 1)
1/ma,res (5)
Fig. 1B shows a graphical illustration of how the MSW is derived.
(ii) The mutation leads to complete resistance. In the case the
mutation makes the viral strain completely resistant against neu-
tralization by antibody a, the viral strain’s ﬁtness is constant for
all antibody concentrations, namely rFsen0 . The lower bound of the
MSW is therefore:
cal = IC50a,sen
(
1
r
− 1
)1/ma,sen
(6)
Whereas the upper bound is cau = ∞.  Fig. 2B shows a graphical illus-
tration of this procedure.
All functions are coded in the R statistical language (R Core Team,
2014) and the scripts are available on request.
3.2. Inﬂuence of the ﬁtness ratio between the Ab-sensitive
ancestral strain and its escape mutant
The width of the MSW  depends on the measured IC50s, the
baseline ﬁtness of the sensitive strain, Fsen0 , and the ﬁtness ratio, r.
Following Rosenbloom et al. (2012), we set the ﬁtness to Fsen0 = 10
for every sensitive strain, which is based on an average of viral ﬁt-
ness measurements in the acute and chronic phase (Davey et al.,
1999; Little et al., 1999; Ioannidis et al., 2000; Funk et al., 2001;
Putter et al., 2002; Krakovska and Wahl, 2007; Ribeiro et al., 2010).
However, the lower bound of the MSW  is independent of the actual
ﬁtness value, Fsen0 . This is the case, because the lower bound is the
antibody concentration at which sensitive and resistant strains’
ﬁtness values (Eqs. 3 and 4) are equal. When determining this con-
centration, Fsen0 cancels out (see also Eq. (6)). Only the upper bound
positively correlates with Fsen0 , in case this bound is not inﬁnite (Eq.
(5)). This means that the ﬁtness value Fsen0 only affects the upper
bound of the MSW.
The ﬁtness ratio r has a large impact on the width of the MSW.
If the resistant strain only decreases the neutralization capacity of
one antibody (case (i)), a small r (close to 0) leads to a small MSW
(see Fig. 3A). If r is smaller than 1/Fsen0 , the ﬁtness of the mutant
strain is below one and the strain cannot outcompete the sensi-
tive strain for any antibody concentration. The closer r comes to 1,
the wider the MSW  becomes. If the resistant strain is completely
insensitive to neutralization of the bnAb (case (ii), Fig. 3B), the lower
bound of the MSW  increases, the closer r comes to 0. If r is greater
or equal to 1, the resistant mutant is ﬁtter than the sensitive strain
for all antibody concentrations. As r has such a big inﬂuence on the
MSW,  we  experimentally determined r as described in Section 2.
3.3. MSW  analysis reveals patterns of Ab induced selective
pressure
Since bnAbs are considered as crucial components of HIV-1 vac-
cines as well as therapeutics (Walker and Burton, 2010; Kwong
et al., 2011; Chen et al., 2013; Haynes and McElrath, 2013; Schiffner
et al., 2013), and evolution of resistant viral strains will lead to their
failure, we were particularly interested in determining the bnAb
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Fig. 4. Infectivity measurement of all viral strains in absence of antibodies. Infectivity of a set input (25 l virus stock solution per 96-well) was  determined for all virus
preparations in 2–4 independent experiments with 3–4 replicates each. The mean of these infectivity values was used to determine the ﬁtness ratio, r, between resistant
and  wild type viral strain by dividing the infectivity of the resistant by the infectivity of the sensitive strain. Table 2 summarizes all pairings of sensitive and resistant viral
strains and their ﬁtness ratios.
concentrations for which a resistant strain can outcompete its viral
ancestor (mutant selection window, MSW).  As we  know from pre-
vious work, bnAb activity is generally lower during cell–cell than
free-virus infection (Abela et al., 2012; Malbec et al., 2013; McCoy
et al., 2014; Gombos et al., 2015; Reh et al., 2015) and mutants have
a higher probability to emerge during cell–cell transmission (Reh
et al., 2015). Hence, it is important to determine MSWs  for both
pathways to aid ﬁnding optimal in vivo doses outside these ranges
to limit resistance evolution.
To this end, we determined the MSW  of 12 pairings of geneti-
cally diverse HIV-1 strains (BG505 (subtype A), JR-FL, JR-CSF, SF162,
REJO, AC10 (all subtype B) and ZM109 (subtype C)) against seven
different bnAbs (b12, 2G12, PG9, PG16, PGT121, PGT128, 2F5). In
each virus/bnAb combination, we compared an antibody sensitive
and a related resistant strain encoding one to two  resistance con-
ferring point mutations. Our current analysis is a proof of principle
study that strictly focuses on mutant selection of single antibody-
virus strain pairs. While similar principles will apply for mutant
selection in vivo, the complexity of determining the precise MSWs
increases as it will be a combined effect of polyclonal antibody
responses against diverse virus populations. We  ﬁrst derived the
ﬁtness ratio between sensitive and resistant strains. To estimate
this ratio, we  determined the efﬁcacy of entry of Env pseudotyped
viruses carrying either bnAb neutralization sensitive or resistant
Envs in free-virus and cell–cell transmission (Fig. 4 and Table 2).
Although our approach restricts the impact of ﬁtness solely to
differences in Env, this is a valid measure for the current analy-
sis because only mutations in Env will occur in direct response
to selective pressure exerted by antibodies. We next performed
antibody inhibition experiments in free-virus and cell–cell trans-
mission with both the sensitive and the resistant strain (Figs. 5–7).
From these experimental data we  obtained measures of IC50
and the Hill-slope parameter, m (Table 2). From these parame-
ters, we then calculated and compared the MSW  for each of the
bnAb-sensitive/resistant virus pairings in free-virus and cell–cell
transmission.
3.3.1. Determining the MSW  for resistance mutations providing
partial decrease in neutralization sensitivity
We ﬁrst applied our theory to a situation where the resis-
tant strain has partially lost its neutralization sensitivity. BG505
is relatively resistant to neutralization by the two V3 crown
Please cite this article in press as: Magnus, C., et al., HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations
leading to escape mutant evolution. Virus Res. (2015), http://dx.doi.org/10.1016/j.virusres.2015.10.009
ARTICLE IN PRESSG ModelVIRUS-96729; No. of Pages 14
8 C. Magnus et al. / Virus Research xxx (2015) xxx–xxx
log(Ab concentration in  µg/ml)
−4 −3 −2 −1 0 1 2
PGT121
PGT128
log(Ab concent ration in µg/ml)
Inhibition Curves Mutant selection windows
free-virus
cell-cell mutant selection
windows (MSW)
IC50
sen
IC50
resL
eg
en
d
co
lo
rs
sh
ap
es sensitive strain
resistant strain
re
si
st
an
t s
tr
ai
n 
ha
s 
lo
w
er
 fi
tn
es
s rfv= 0.54, rcc=0.36
r
fv
= 0.54, r
cc
=0.36%
In
hi
bi
tio
n 
PGT121
PGT128
-4 -2 0 2
0
50
100
-4 -2 0 2
0
50
100
Fig. 5. Antibody inhibition curves and mutant selection windows for PGT121 and PGT128. The PGT121 and PGT128 sensitive strain BG505 T332N and the resistant BG505
strain are used as hypothetical escape pair to illustrate the impact of the MSW of the bnAbs PGT121 and PGT128. Black symbols refer to free-virus spread and red symbols
refer  to cell–cell spread. The gray shaded areas mark the displayed antibody concentration and the dark gray shaded area displays the combined MSW  for free-virus and
cell–cell transmission.
glycan dependent bnAbs PGT121 and PGT128 reﬂected by the
comparatively high IC50 concentrations needed to block this
strain (free-virus and cell–cell transmission IC50 of 0.26/1.7 and
1.9/2.8 g/ml, respectively). Resistance in BG505 is inferred by loss
of the N-glycosylation site at amino acid position 332 which is cru-
cial for several bnAbs including PGT121, PGT128 and 2G12 (Sanders
et al., 2002; Scanlan et al., 2002; Calarese et al., 2003; Pejchal et al.,
2011; Julien et al., 2013; Sok et al., 2014). A variant with a functional
N332 site, BG505 T332N, has a restored sensitivity to PGT121 and
PGT128 (free-virus and cell–cell transmission IC50 of 0.0037/0.39
and 0.0039/0.48 g/ml for PGT121 and PGT128, respectively). We
thus used the sensitive strain BG505 T332N and the resistant BG505
strain as hypothetical escape pair to illustrate the impact of the
MSW  of the bnAbs PGT121 and PGT128 in this setting. Impor-
tantly, we found that the Env of BG505 is less ﬁt in comparison
to BG505 T332N with a ﬁtness ratio of r = 0.33. In Fig. 5 we show
the mutant selection windows for the sensitive strain BG505 T332N
and its resistant mutant variant BG505 as a function of the antibody
concentrations of PGT121 and PGT128 together with the measured
IC50 values. The direct comparison of the MSWs  in both free-virus
and cell–cell transmission of the two Abs in these settings revealed
that while the MSW  of both pathways was overall in a compa-
rable range for both bnAbs (within 1 order of magnitude), there
were bnAb-dependent differences. PGT128 had a relatively wide
MSW for free-virus (0.0029– 12.7 g/ml) which overlaps with this
of cell–cell transmission (0.69–5.29 g/ml). PGT121, however, has
almost non-overlapping MSWs  in the two transmission pathways.
Of note, the actual IC50 values of the two Abs in the two  transmis-
sion modes do not provide information on the respective MSWs,
highlighting the importance to assess the MSW  speciﬁcally. When
the resistant mutation does not lead to a complete loss in neutral-
ization activity, antibody treatment without risking that a speciﬁc
resistance mutation arises is possible, provided that the chosen
Ab concentration is higher than the upper bound of the MSW  for
both, free-virus and cell–cell transmission. However, doses that are
required can be quite high: In the example depicted in Fig. 5, con-
centrations of more than 10 g/ml of PGT121 would be required to
suppress mutant selection in vitro.
3.3.2. Complete resistance: one virus tested against different
antibodies
During the course of an HIV-1 infection, the immune system
produces a vigorous polyclonal antibody response to the envelope
trimer. Thus, viral strains are under selective pressure exerted by
many different antibody speciﬁcities. To mimic such a situation,
we tested ﬁve different broadly neutralizing antibodies (b12, 2G12,
2F5, PG9 and PG16) against various JR-FL variants that either confer
sensitivity (PG9 and PG16) or resistance (b12, 2G12, 2F5) compared
to the parental JR-FL strain (Fig. 6, Table 2). In all combinations
probed, the resistant variant was  a complete Ab escape variant. In
the cases of b12- and 2G12- sensitive/resistant viral strains, the
resistant strains had lower relative ﬁtness values (r < 1) than the
sensitive strain in both transmission pathways. In the cases of 2F5-
, PG9- and PG16-sensitive/resistant viral strains, the resistant strain
had higher ﬁtness (r > 1) (Table 2). Fig. 6 shows that complete resis-
tance of the arising mutation has a huge impact on the width of
the MSW.  There is no residual effect of the Ab on the mutant virus
and this variant can therefore evolve and outcompete its sensitive
viral ancestor at any antibody concentration higher than the lower
bound of the MSW.  Considering that inhibition in free-virus is more
effective (reﬂected by lower IC50 values), the MSW  for free-virus
inhibition can cover a wider concentration range (starting already
at lower Ab concentration) than the MSW  for cell–cell transmission,
as e.g. seen for 2F5 and 2G12. In several of the studied virus pairings,
the mutant virus proved to have higher entry ﬁtness. While in vivo
initially emerging mutations are likely less ﬁt than the parental
strains, increases in ﬁtness may  nevertheless occur in the course
of accumulating replication compensating mutations. In the sce-
narios where the resistant mutant has higher ﬁtness (bnAbs 2F5,
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(red  symbols) transmission. The gray shaded areas mark the displayed antibody concentration and the dark gray shaded area displays the combined MSW  for free-virus and
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PG9, PG16), the MSW  covers the entire range of possible antibody
concentrations.
3.3.3. Complete resistance: comparative analysis of one bnAb
against divergent viral strains
Antibodies as components of vaccines or therapeutics need to
be active against genetically diverse viruses of different subtypes
as they face different inocula compositions and high within-host
diversity, respectively. We  therefore compared the MSWs  of one
antibody, PG9, against diverse viruses (Fig. 7 and Table 2). The
N-glycosylation site N160 is crucial for PG9 activity and for the
functional integrity of the virus envelope of many strains, as loss
of N160 is frequently associated with severely decreased infectivity
(Brandenberg et al., 2014). The wild type virus strains REJO, ZM109,
AC10 and JR-CSF are sensitive to PG9 neutralization. Upon chang-
ing the asparagine to lysine at position 160, the strains become
completely resistant to PG9 neutralization. The SF162 wild type
strain already carries a PG9 resistance conferring lysine at posi-
tion 160 such that we  introduced an asparagine at this position to
obtain a matching SF162 viral strain sensitive to PG9 neutraliza-
tion. We  used Eq. (6) to determine the lower bound of the MSW,
as all probed mutant strains were completely resistant against
PG9. Fig. 7 shows that the MSWs  are quite diverse and how much
these ranges are governed by the ﬁtness ratio. If a 100% resistance
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conferring mutant has an infectivity comparable to the sensitive
parental virus (e.g. SF162 during cell–cell transmission, r = 0.9747),
the MSW  is extremely wide. Therefore, the mutant can be selected
for and survive at essentially any antibody concentration. For viral
strains that do not have such an extreme MSW,  the MSW  of free-
virus and cell–cell transmission should be considered to prevent
a resistant viral variant to arise via either route, when the bnAb
is used as treatment. However, it is important to consider that
the antibodies can have substantially different efﬁcacies in the
cell–cell and free-virus transmission pathways. For ZM109 and JR-
CSF, the neutralization resistant viral strains had such low ﬁtness
values in free-virus transmission that replication and therefore the
evolution of the particular Ab resistant mutant can only occur
in cell–cell transmission. In most cases, the MSW  for cell–cell
transmission is wider than for free-virus transmission (Fig. 7). How-
ever, the MSW  of REJO inhibited by PG9 in free-virus transmission
starts at a lower concentration than for cell–cell transmission. This
ﬁnding highlights the necessity to determine the MSW  for both
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transmission routes. In sum, our results reveal that it is unlikely
to reach effective concentrations for single bnAb treatments in vivo
that will reliably prevent resistant strains to emerge as long as point
mutations can evolve that provide complete resistance without any
major ﬁtness cost.
4. Synthesis, discussion and outlook
Any antiviral treatment strategy must reduce viral loads but
also prevent treatment failure caused by the evolution of treat-
ment resistant viral strains. Broadly neutralizing antibodies against
HIV-1 which are considered lead components of novel therapeu-
tic approaches and vaccines (Burton et al., 2012; Schiffner et al.,
2013), have different neutralization potencies in free-virus and
cell–cell transmission (Abela et al., 2012; Malbec et al., 2013; McCoy
et al., 2014; Gombos et al., 2015; Reh et al., 2015). Therefore,
both pathways need to be considered when assessing the efﬁcacy
of antibody treatment. In the current study, we determined the
potential impact of the two transmission pathways in fostering
the occurrence of virus strains that acquired resistance mutations
conferring partial or complete resistance to antibody neutraliza-
tion. In particular, we investigated whether concentration ranges
exist that prevent mutant selection in both pathways, hence, allow-
ing optimal dosing of therapies. To this end, we extended the
framework of mutant selection windows (Baquero and Negri, 1997;
Rosenbloom et al., 2012) to determine the antibody concentration
ranges for which a speciﬁc antibody escape variant can outcompete
its ancestral strain. To obtain the crucial parameters for the MSW
framework, we measured the inhibitory potential of broadly neu-
tralizing antibodies against neutralization sensitive and resistant
viral strains in assay systems that allow for separation of cell–cell
from free-virus transmission in vitro.
In contrast to our previous work (Reh et al., 2015), where we
showed that an observed mutant variant has more likely arisen
during the cell–cell pathway, we determined here the concentra-
tion ranges for which an escape variant can outcompete its viral
ancestor. When these MSWs  for free-virus and cell–cell transmis-
sion overlap, the escape variant can arise via both transmission
routes. However, if the MSW  for cell–cell transmission is wider than
the MSW  for free-virus transmission, the cell–cell route may  serve
as a rescue pathway for the virus to evolve resistant viral variants.
Across all viruses and antibodies probed, we saw that MSWs  for
both transmission pathways are generally very wide. Thus, it will
be difﬁcult, if not impossible, to determine concentration ranges
that prevent mutant selection in vivo. Our ﬁndings are in line with
what we know from antibody efﬁcacy in established HIV-1 infec-
tion where escape to single antibody pressure occurs univocally
unless antibodies are highly potent and present at doses orders of
magnitude higher than their in vitro effective concentrations (Frost
et al., 2005; Trkola et al., 2005; Klein et al., 2012; Overbaugh and
Morris, 2012; Barouch et al., 2013; Wibmer et al., 2013; Caskey et al.,
2015). Our study provides additional proof that combining different
antibody speciﬁcities in a treatment regime will be crucial because
multiple escapes will most likely be more difﬁcult to achieve and
these mutations will in most cases come with a strong ﬁtness cost
for the virus. Indeed, as we showed here, the impact of the ﬁtness
ratio between the sensitive and the resistant strain proved deci-
sive for the width of the MSW.  Hence, treatments for which escape
mutations severely impact infectivity are of tremendous advantage.
It will be intriguing to extend the MSW  framework to include
further biologically relevant parameters. In addition to studying
antibody inhibition that reaches 100% efﬁcacy, it may  be important
to explore antibodies with lower efﬁcacy, i.e. with activity plateaus
below 100%. Such scenarios can be integrated into our framework
by adapting the infectivity reduction in Eqs. (3) and (4). Antibody
concentrations can vary over time and also between body compart-
ments. Similar to a framework introduced for drug induced escape
mutant strains (Rosenbloom et al., 2012), the MSW  framework can
be extended to predict the timing of the occurrence of a viral escape
mutant upon selective pressure induced by antibodies. To this end,
the exact sequence of the wild type and mutant strain must be
known to determine the probability that the mutant strain can arise
during reverse transcription. By taking into account neutralization
levels, the mutation probability can then be used in combination
with a virus dynamics model to predict the dynamics of the wild
type and mutant on a population level. However, unlike drug resis-
tance where often a single or very few mutations are sufﬁcient to
infer resistance, escape to neutralizing antibodies is much more
complex as the envelope has ample possibilities of evading neu-
tralizing antibodies. Besides mutating the antibody’s binding site,
the Env can evade antibody recognition by altering its shielding
properties (e.g. by modiﬁcation of the V1V2 loop), by increasing
or alternating the glycan shield and by introducing mutations at
distant sites in the envelope that induce conformational shifts that
either affect access of the antibody epitope or the conformation of
the antibody’s binding site itself (Rusert et al., 2011; Kwong et al.,
2011).
Our current study is a ﬁrst step towards deﬁning the impact of
the MSW.  Here we  relied solely on in vitro assays using engineered
cell lines and Env-pseudotyped viruses. The ﬁtness measurements
we made are therefore only referring to differences in entry capac-
ity of the virus strains. Assessment of in vivo derived strains which
will harbor a range of mutations that shape ﬁtness also in unrelated
genes will be important to include in future studies. The resis-
tance mutations we  assessed are speciﬁc point mutations known
to eliminate the respective antibody epitopes. However, the in
vivo mutant selection process will be iterative involving several
rounds of acquiring resistance conferring mutations and compen-
sating mutations that improve ﬁtness. As laid out in Section 3.2,
the ﬁtness of the sensitive strain only impacts the upper but no
the lower bound of the MSW  and the ratio between sensitive and
resistant strains’ ﬁtness has a tremendous impact on the MSW.  Both
quantities need to be determined individually for an exact deter-
mination of the MSWs.  Hence, determining the in vivo MSWs  will
be more complex and will need challenging longitudinal assess-
ment of emerging viruses and autologous neutralization responses
(Trkola et al., 2008; van Gils and Sanders, 2014).
It is important to note, that the MSWs  deﬁned here are solely
based on in vitro experiments, with their intrinsic assay limitations
of cell type used and maximal antibody concentrations. While sim-
ilar relationships between infectivity and efﬁcacies of antibodies
in free-virus and cell–cell transmission can be assumed in vivo,
the doses determined for MSWs  in the present study cannot be
directly transferred to in vivo situations where other factors like
tissue distribution and half-life of the mAb  and contribution of
antibody effector functions also come into play. It is, however,
intriguing that the upper bounds of the MSW  we  determined here
are orders of magnitude higher than the in vitro determined IC50
values which compares well with the discrepancy between in vitro
and in vivo effective antibody titers described to be 100–1000-fold
higher (Parren et al., 2001; Trkola et al., 2005, 2008; Hessell et al.,
2009; Moldt et al., 2012; Reh et al., 2015). While these high in vivo
effective concentrations cannot be tested in vitro, in vitro measured
inhibitory activities correlate with the in vivo concentrations (van
Gils and Sanders, 2014).
Intriguingly, the MSW  can be even wider in a setting where
the antibody has less efﬁcacy (e.g. during cell–cell transmission).
This is most often the case, when the difference between antibody
efﬁcacy for the sensitive and resistant strain is less pronounced in
free-virus in comparison to cell–cell transmission. Detailed stud-
ies on the efﬁcacy of neutralization during cell–cell transmission
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especially those considering the stoichiometry of entry and neu-
tralization will be crucial to deﬁne the underlying mechanisms of
efﬁcacy loss.
Based on our ﬁndings, we suggest to consider the MSW when
analyzing or even predicting the outcome of passive immuniza-
tion studies currently conducted with bnAbs to prevent or treat
HIV-1 infection (Mascola et al., 2000; Trkola et al., 2005; Hessell
et al., 2009, 2010; Moldt et al., 2012; Barouch et al., 2013; Halper-
Stromberg et al., 2014; Klein et al., 2014; Doria-Rose et al., 2014;
Caskey et al., 2015). This may  provide valuable information towards
neutralizing antibody efﬁcacy in vivo and the processes that lead
to within-host mutant selection through free-virus and cell–cell
transmission.
Our analysis highlights the difﬁculties in dose ﬁnding for
neutralizing antibody therapy and provides novel insights why
neutralization resistance selection in HIV-1 infection may  be so
effective. As we show here, both free-virus and cell–cell transmis-
sion provide possibilities for speciﬁc virus mutants to emerge over
large antibody concentration ranges. Hence, strategies are needed
to limit the MSW  to narrow concentration ranges and to increase
antibody pressure in a way that resistance mutations come with
severe ﬁtness costs. Combination therapy with several antibodies
targeting different epitopes on the virus envelope may  be one way
to achieve this goal.
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